v1.0

Change Notification for the UK Blood Transfusion Services

No. 21 - 2025

Transgender and Non-Binary Individuals

This notification includes the following changes:

	BM-DSG Bone Marrow & Peripheral Blood Stem Cell	CB-DSG Cord Blood	GDRI Geographical Disease Risk Index	TD-DSG Tissue - Deceased Donors	TL-DSG Tissue - Live Donors	WB-DSG Whole Blood & Components	Red Book Guidelines for the BTS in the UK
1. Transgender and Non-Binary Individuals				•	•		
2. Changes to the A-Z index				•	•		

Dr Richard Lomas

fre for

Chair, Standing Advisory Committee on Tissues (SACT)

Dr Stephen Thomas

Professional Director of JPAC

Changes are indicated using the key below. This formatting will not appear in the final entry.

original text «inserted text» deleted text

v1.0

1. Changes apply to both Tissues (Deceased and Live Donors) DSGs

Transgender «and Non-Binary» Individuals

(revised entry)

Definition	«Transgender and non-binary individuals			
	Trans is an umbrella term to describe people whose gender is not the same as, or does not sit comfortably with, the sex they were assigned at birth. Trans people may describe themselves using one or more of a wide variety of terms including (but not limited to) transgender, non-binary or gender queer. Gender affirming hormone therapy may be used as part of transition by transgender and non-binary individuals.»			
	Cisgender (cis) describes someone whose gender identity is the same as the sex they were assigned at birth.			
	Transgender (trans) describes someone whose gender is not the same as, or does not sit comfortably with, the sex they were assigned at birth.			
Obligatory	«Obtain history and refer to designated medical officer if necessary.»			
	Assessment of the donor suitability should be according to the gender assigned at the time of donation.			
Discretionary	Obtain history and refer to designated medical officer if necessary.			
See if Relevant	« <u>Hormone Replacement and Sex Hormone Therapy</u> »			
	<u>Tissues Safety Entry</u>			
Additional Information	« Assessment of the donor suitability should be according to the gender assigned at the time of donation.»			
	An individual risk assessment is required with regard to potential effects on the donor, donated material and any potential risk to the recipient.			
	Consideration should be given to the medications used during gender re- assignment. «As well as hormones, donors may take other medication to modify the effect of sex hormones as part of gender-affirming treatment. This may include hormone blockers, such as anti-androgens.»			
Reason for Change	«Title changed, definition amended, obligatory section amended, discretionary section deleted, link to 'Hormone Replacement and Sex Hormone Therapy' entry added, and additional information section updated.»			
	This entry was revised to support the implementation of the FAIR III report; the additional information section has been revised to reflect the circumstances of tissue and cell donations.			



v1.0

2. Changes apply to both Tissues (Deceased and Live Donors) DSGs

The following redirections will be <u>amended</u> in the **A-Z index**

Gender Reassignment » Transgender and Non-Binary Individuals

Sex Change » Transgender and Non-Binary Individuals